Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Retagliptin and Metformin on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Retagliptin and metformin is a two-in-one diabetes tablet developed in China by Jiangsu Hengrui Pharmaceuticals, with Shandong Shengdi Pharmaceutical as the licence holder. The 50 mg/850 mg strength is sold as 瑞霖唐® (Ruilintang). Each tablet combines retagliptin, a DPP-4 inhibitor developed in China, with metformin, the long-established first-line diabetes medicine, so patients take one tablet instead of two.
China's National Medical Products Administration (NMPA) approved it in May 2025 for:
It is a prescription diabetes and hormone medicine and should be used under an endocrinologist, diabetologist or physician.
The two medicines tackle high blood sugar in different ways. Retagliptin blocks the DPP-4 enzyme, so the body's own GLP-1 hormone stays active for longer and the pancreas releases more insulin, and less glucagon, when sugar is high. Metformin, a biguanide, lowers the amount of sugar the liver releases and helps the body respond better to insulin. The tablet is made in two layers, so each medicine is kept separate and released on its own.
In the phase 3 HR-SP2086-303 trial, 371 adults whose diabetes was not controlled on metformin alone added either retagliptin 50 mg twice a day or a placebo. After 24 weeks, average HbA1c fell by 1.18% from where it started, 0.62% more than with placebo. 40.5% reached an HbA1c below 7%, against 20.5% on placebo, and there were no severe low-sugar episodes. A bioequivalence study then showed that the combined tablet delivers the same amount of each medicine to the blood as taking retagliptin and metformin tablets separately.
Your doctor will pick the strength and check kidney function before and during treatment.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Metformin and lactic acidosis: metformin can rarely cause lactic acidosis, a dangerous build-up of acid in the blood. The US metformin label lists the main risk factors as kidney impairment, age 65 or over, X-ray scans with contrast dye, surgery, severe heart failure or low oxygen states, heavy alcohol use and liver impairment. Metformin is not used when eGFR is below 30, and it is usually paused around contrast scans and surgery. Seek urgent help for unexplained fast breathing, muscle pain, unusual tiredness or sleepiness, or stomach pain.
Side effects in the trial: the only side effect seen in at least 1% of patients taking retagliptin with metformin was raised uric acid (1.3%). No serious side effects were linked to treatment, and the combined tablet did not add side effects compared with taking the two medicines separately. Safety in pregnancy, breastfeeding and children has not been established in the published data, so discuss this with your doctor first.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. This combination is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and neither it nor retagliptin on its own has been approved by the US FDA or the European Medicines Agency.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because diabetes treatment is long term, your doctor will plan supply in regular batches.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. At one tablet twice a day, a month of treatment needs about 60 tablets, and we order the exact strength written on the prescription. The tablets travel in their sealed original packs under temperature-controlled shipping and should be stored as directed on the pack. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid doctor's prescription.
Diabetes specialists in Delhi see patients from all over North India, and our New Delhi dispatch point keeps delivery quick.
Doctors in Mumbai can request the right strength for a named patient and set up repeat batches so treatment never runs out.
Patients in Bangalore can have the tablets sent home once the prescription and kidney report are checked.
Diabetologists in Chennai can share the prescription and recent HbA1c with us to start the import.
Endocrinologists in Hyderabad can coordinate access, with the quote shared in writing before any order is placed.
For Kolkata and the eastern states, we time each batch so the next arrives before the current one is finished.
Patients in Pune can use the same documented import route, with updates at each step.
Physicians in Ahmedabad can arrange supply for patients who would benefit from one combined tablet.
Patients in Jaipur and across Rajasthan can receive the tablets at home or at their clinic.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating clinic.
We coordinate deliveries to patients and hospitals across Uttar Pradesh after the documents are complete.
Patients across Kerala can receive the medicine in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
